<DOC>
	<DOCNO>NCT00153101</DOCNO>
	<brief_summary>The Ongoing Telmisartan Alone combination wiht Ramipril Global Endpoint trial ( ONTARGET ) : The primary objective determine ( ) telmisartan 80mg daily ramipril 10mg daily combination therapy effective reduce composite endpoint Cardiovascular Death ( CV ) death , Myocardial infarction ( MI ) , stroke hospitalization Congestive Heart Failure ( CHF ) compare ramipril 10mg alone ; ( b ) telmisartan 80mg daily least effective ( i.e . less effective ) ramipril 10mg daily , endpoint . Telmisartan Randomised Assessment Study Angiotension convert Enzyme inhibitor intolerant subject Cardiovascular Disease . ( TRANSCEND ) : The primary objective study determine treatment telmisartan 80mg daily superior placebo reduce composite endpoint Cardiovascular Death ( CV ) , Myocardial Infarction ( MI ) I , stroke hospitalization Congestive Heart Failure ( CHF ) patient intolerant Angiotension Converting Enzyme inhibitor .</brief_summary>
	<brief_title>Effectiveness Safety Ramipril Alone Compared With Telmisartan Alone Combination With Ramipril Patients High Risk Cardiovascular Events . Patients Intolerant Ramipril Were Entered TRANSCEND , Telmisartan Compared Placebo .</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Coronary Artery Disease : Previous Myocardial infarction ( &gt; 2 day prior informed consent ) , stable previous unstable angina ( &gt; 30 day prior informed consent ) document multivessel coronary artery disease positive stress test , multivessel Percutaneous Transluminal Coronary Angioplasty ( &gt; 30 day prior informed consent ) , previous multivessel Coronary Artery Bypass Grafting without angina ( surgery perform &gt; 4 year prior inform consent ) recurrent angina surgery . Other High Risk : 1 . Peripheral Arterial Disease : Previous limb bypass surgery angioplasty amputation , intermittent claudication history ankle/arm Blood Pressure ratio &lt; 0.8 least one side , significant stenosis angiography noninvasive test 2 . Previous stroke 3 . Transient ischemic Attack &gt; 7 day &lt; 1 year prior inform consent 4 . Diabetes Mellitus ( type I II ) : evidence endorgan damage ( retinopathy , Left ventricular hypertrophy , micro macro albuminuria ) , evidence previous cardiac vascular disease . No definite specific indication contraindication study treatment . Written informed consent . A . Medication use : 1 . Inability discontinue Angiotension Converting Enzyme ( ACE ) inhibitor Angiotension 2 receptor antagonist ( AIIAs ) . 2 . Patients know hypersensitivity intolerance Angiotension 2 receptor antagonist ( AIIAs ) Angiotension Converting Enzyme ( ACE ) inhibitor . NOTE : Patients know intolerance Angiotension Converting Enzyme inhibitor intolerance ( ACEI ) enrol TRANSCEND study . B. Cardiovascular disease : 1 . Symptomatic congestive heart failure . 2 . Hemodynamically significant primary valvular outflow tract obstruction ( e.g . aortic mitral valve stenosis , asymmetric septal hypertrophy , malfunction prosthetic valve ) . 3 . Constrictive pericarditis . 4 . Complex congenital heart disease . 5 . Syncopal episodes unknown etiology &lt; 3 month inform consent . 6 . Planned cardiac surgery angioplasty within three month . 7 . Uncontrolled hypertension treatment ( i.e.Blood pressure ( BP ) &gt; 160/100 ) . 8 . Heart transplant recipient . 9 . Strokes due subarachnoid hemorrhage C. Other condition : 1 . Significant renal disease define : 1 . Renal artery stenosis ; 2 . Creatinine clearance &lt; 0.6 ml/min serum creatinine &gt; 265 umol/L ( &gt; 3.0 mg/dL ) ; 3 . Hyperkalemia : potassium &gt; 5.5 mmol/L . 4 . Proteinuria* ( TRANSCEND ) . 2 . Hepatic dysfunction define follow laboratory parameter : Serum Glutamate Pyruvate Transaminase ( SGPT ) Alaninaminotransferase ( ALT ) Serum Glutamic Oxaloacetic Transaminase ( SGOT ) Aspartate aminotransferase ( AST ) &gt; 4 time upper limit normal additional criterion hepatic impairment upper limit normal range , total Bilirubin &gt; 20 umol/L , biliary obstructive disorder . 3 . Uncorrected volume depletion sodium depletion . 4 . Primary aldosteronism . 5 . Hereditary fructose intolerance . 6 . Any major noncardiac illness expect reduce life expectancy interfere study participation . 7 . Patient simultaneously take another experimental drug . 8 . Patient significant disability precludes regular attendance clinic followup . 9 . Patient sufficient disability incapacity preclude regular attendance clinic followup . 10 . Unable unwilling provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>